+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Sex- and Age-Related P75 Neurotrophin Receptor Expression in the Human Supraoptic Nucleus

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The human supraoptic nucleus (SON) is the main production site of plasma vasopressin. Previously, using the Golgi apparatus and cell size as measures for neuronal metabolic activity, an activation of vasopressinergic neurons was found during ageing in the human SON in women but not in men. We hypothesized that the low-affinity neurotrophin receptor p75 (p75<sup>NTR</sup>) might be involved in the mechanism of activation of vasopressin neurons in postmenopausal women, since this receptor was found to be expressed in the SON neurons of aged individuals, and because p75<sup>NTR</sup> expression was shown to be suppressed by estrogens. Therefore, we investigated whether p75<sup>NTR</sup> immunoreactivity in the SON neurons was age- and sex-dependent. For this purpose, we studied paraffin sections of the SON in 32 postmortem brains of control patients ranging in age from 29 to 94 years with an anti-p75<sup>NTR</sup> antibody and determined the area of p75<sup>NTR</sup> immunoreactivity per neuron using an image analysis system. To study whether the p75<sup>NTR</sup> might also participate in the activation of SON neurons, we related Golgi apparatus size to the area of p75<sup>NTR</sup> immunoreactivity per cell in the same patients. We found that the area of p75<sup>NTR</sup> immunoreactivity per cell correlated indeed significantly with age and with Golgi apparatus size only in women but not in men. Therefore, our results suggest that p75<sup>NTR</sup> is involved in postmenopausal activation of vasopressinergic neurons in the human SON.

          Related collections

          Most cited references 18

          • Record: found
          • Abstract: not found
          • Article: not found

          Comparative distribution of estrogen receptor-? and -? mRNA in the rat central nervous system

            • Record: found
            • Abstract: found
            • Article: not found

            High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor.

            Nerve growth factor (NGF) interacts with two different low-affinity receptors that can be distinguished by affinity crosslinking. Reconstitution experiments by membrane fusion and transient transfection into heterologous cells indicate that high-affinity NGF binding requires coexpression and binding to both the low-affinity NGF receptor and the tyrosine kinase trk gene product. These studies reveal a new growth factor receptor-mediated mechanism of cellular differentiation involving trk and the low-affinity NGF receptor.
              • Record: found
              • Abstract: found
              • Article: not found

              Neurotrophic factors: from molecule to man.

              Recent advances in the understanding of the physiological role of nerve growth factor (NGF) have raised the question of whether neurotrophic factors might have clinical potential in the treatment of neurodegenerative disease or nerve trauma. Although NGF was first characterized as a target-derived survival factor for developing sympathetic and sensory neurons, it is now clear that it plays an important role in the maintenance and regeneration of mature peripheral neurons. However, the highly restricted specificity of NGF for sympathetic neurons, subpopulations of neural-crest-derived sensory neurons, and striatal and basal forebrain cholinergic neurons has, for almost two decades, stimulated the search for other neurotrophic factors that might act on the many classes of neurons that do not respond to NGF. In this article, the biology of the recently discovered NGF-related family of neurotrophic factors and ciliary neurotrophic factor and their receptors are reviewed, especially in the context of the therapeutic potential of these factors in the treatment of neurological disorders of the CNS.

                Author and article information

                S. Karger AG
                April 2000
                17 April 2000
                : 71
                : 4
                : 243-251
                aNetherlands Institute for Brain Research, Amsterdam, The Netherlands; bDepartment of Histology and Embryology, Kursk State Medical University, Kursk, Russia
                54542 Neuroendocrinology 2000;71:243–251
                © 2000 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 3, Tables: 2, References: 57, Pages: 9
                Reproductive Neuroendocrinology


                Comment on this article